Phase 3 Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are willing and able to complete all parts of the study — including MRI scans, genetic testing, and PET or spinal fluid tests — for the full duration, either on their own or with help from a study partner
- People whose vision and hearing are good enough, in the investigator's judgment, to complete memory and thinking tests (glasses and hearing aids are allowed)
- People who have evidence of Alzheimer's disease confirmed by an amyloid PET scan, or by a spinal fluid test measuring certain protein levels if a PET scan is not available
- People who have been diagnosed with probable Alzheimer's dementia or mild cognitive impairment due to Alzheimer's disease (also called Alzheimer's clinical Stage 3 or Stage 4)
- People whose scores on two standard memory and thinking assessments fall within a specific range at screening (MMSE score of 22 or above, and a CDR-GS score of 0.5 or 1.0)
- People who have a reported history of gradual memory or thinking decline that started and progressed over at least the 1 year before screening
- People whose score on a specific memory test (the RBANS Delayed Memory Index) is 85 or below (confirm with trial site)
- People who have a "study partner" available, as defined by the trial protocol
Who may not be able to join:
- People who have any condition other than Alzheimer's disease that could affect memory or thinking
- People who have a history of, or currently have, significant disease affecting blood flow in the brain (such as strokes)
- People who have had a severe brain injury that caused lasting neurological damage or structural brain changes
- People who have a history of, or currently have, a significant growth or mass inside the skull
- People whose MRI scan shows significant abnormalities in the brain, or who are unable to tolerate or safely undergo an MRI
- People who have other serious medical conditions — such as heart, liver, or kidney disease — that are not stable or well-controlled, or that the investigator believes could affect the person's safety or interfere with study results
- People who have a history of cancer, unless the cancer is considered cured or carries a very low risk of spreading or causing serious harm
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Clinical Trials, Hoffmann-La Roche
Phone: 888-662-6728
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change from baseline to Week 72 in Clinical Dementia Rating, Sum of Boxes (CDR-SB)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.